Practical consensus recommendation on when to do BRCA testing

Author:

Parikh Purvish M.1,Wadhwa J.2,Minhas S.3,Gupta A.4,Mittal S.5,Ranjan S.6,Mehta P.7,Singh R.8,Kataria S. P.9,Salim S.10,Ahmed M.11,Aggarwal S.3

Affiliation:

1. Department of Oncology, Shalby Cancer and Research Institute, Mumbai, Maharashtra

2. Department of Medical Oncology, Medanta Hospital, Gurugram, Haryana

3. Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi

4. Department of Radiation Oncology, Safdarjung Hospital, New Delhi

5. Department of Medical Oncology, Action Balajee Cancer Center, New Delhi

6. Department of Medicine, INHS Sanjivani, Kochi, Kerala

7. Department of Medical Oncology, Asian Institute of Medical Sciences, Faridabad, Haryana

8. Department of Medical Oncology, Artemis Hospital, Gurugram, Haryana

9. Department of Medical Oncology, Safdarjung Hospital, New Delhi

10. Department of Oncology, Hakim Sanaullah Cancer Center, Baramulla, Jammu and Kashmir

11. Department of Radiation Oncology, Jolly Grant Himalayan Institute, Dehradoon, Uttarakhand

Abstract

Abstract BRCA-mutation associated breast cancer and to future cancer risks and sensitivity to systemic therapies. Now that rapid genetic testing for BRCA1 and BRCA2 mutations is available, BRCA mutation status can be considered when making treatment and prevention decisions for BRCA testing, BRCA mutation carriers with breast cancer. Expert group used data from published literature, practical experience, and opinion of a large group of academic oncologists, to arrive at practical consensus recommendations for use by the community oncologists.

Publisher

Georg Thieme Verlag KG

Subject

Cancer Research,Oncology

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Breast Cancer in India;Hematology/Oncology Clinics of North America;2024-02

2. Breast Cancer Scenario in India;Breast Cancer;2022

3. A quality evaluation of the clinical practice guidelines on breast cancer using the RIGHT checklist;Annals of Translational Medicine;2021-07

4. Why we should rely only on molecular tests based on Indian data;International Journal of Molecular & Immuno Oncology;2020-05-13

5. Risk reduction strategies in BRCA patients: An Indian perspective;Indian Journal of Medical and Paediatric Oncology;2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3